Sign up United Kingdom
Proactive Investors - Run By Investors For Investors
Why invest in CLL?
Cello Health plc: THE INVESTMENT CASE
INVESTMENT OVERVIEW

Cello Health sees half-year profits climb almost 10%

“Cello Health is successfully building its early stage asset development advisory platform for biotech clients, as well as growing its core later stage and post-launch franchise with pharmaceutical clients”
ipad
INVESTMENT OVERVIEW: CLL The Big Picture
Cello is making good progress with its plans to crack the US

Healthcare-focused advisory group Cello Health PLC (LON:CLL) has reported a rise in half-year profits, driven by another six months of strong growth from its Cello Health division.

The company has two arms: Health, which provides expertise, processes, intellectual property and market knowledge spanning the pharmaceutical, biotechnology, diagnostics, healthcare equipment and consumer health sectors.

READ: Cello makes strong start to the year

And Signal, which provides “digital, social media and branding expertise” to companies. This division used to be focused sectors such as technology and retail, but it has taken a much greater interest in health of late.

Cello’s claim to fame is that it works with 24 of the top 25 pharmaceutical companies around the world.

Operating profits in the Health business climbed 16.1%, while they edged 3.9% higher in the Signal division, driven by improved margins.

Overall, group revenue was broadly flat at £78.5mln in the six months ended June 30, while pre-tax profits jumped 9.3% to £5.1mln (H1 17: £4.6mln).

Cello has been expanding across the pond over the past year or so and the US now accounts for almost half of its profit. The US businesses it acquired last year as part of this drive continue to perform well, the company said.

Given the strong bottom-line performance, Cello has raised its dividend by 5% to 1.1op (H1 17: 1.05p).

Chairman stepping down

“Cello Health is successfully building its early stage asset development advisory platform for biotech clients, as well as growing its core later stage and post-launch franchise with pharmaceutical clients,” said chief executive Mark Scott.

“The depth and breadth of client relationships held by Cello Health under Master Service Agreements (MSAs) is impressive, underpinning revenue visibility.

“The leadership team is actively engaged with increasing the size of the global service platform, including Signal's communications capabilities. Signal, and particularly Pulsar, is rapidly building its healthcare franchise.

“The vision of developing Cello Health into a leading global advisor to healthcare and related clients is taking shape.”

Within the announcement, long-term chairman Allan Rich announced he is to retire from the board of directors. He will be replaced by current non-executive Chris Jones.

Shares were up 1.5% to 135p shortly before market close in London.

-- Updates for video link and share price --

View full CLL profile View Profile

Cello Health plc Timeline

Related Articles

Lego ball
September 14 2018
The company's latest push is a joint venture agreement with US-based entertainment firm Three Six Zero, which has steered the careers of pop stars such as Calvin Harris
Apollo 11
February 22 2018
Immersive VR, a technology company focused on the education space, was the first company Sure backed
Students in a class
August 27 2018
The company is gaining traction in Asia where people are looking to take language courses to work or study internationally

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use